The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Proteome-based plasma biomarkers for Alzheimer's disease
Open accessAbstract
Alzheimer's disease is a common and devastating disease for which there is no readily available biomarker to aid diagnosis or to monitor disease progression. Biomarkers have been sought in CSF but no previous study has used two-dimensional gel electrophoresis coupled with mass spectrometry to seek biomarkers in peripheral tissue. We performed a case-control study of plasma using this proteomics approach to identify proteins that differ in the disease state relative to aged controls. For discovery-phase proteomics analysis, 50 people with Alzheimer's dementia were recruited through secondary services and 50 normal elderly controls through primary care. For validation purposes a total of 511 subjects with Alzheimer's disease and other neurodegenerative diseases and normal elderly controls were examined. Image analysis of the protein distribution of the gels alone identifies disease cases with 56% sensitivity and 80% specificity. Mass spectrometric analysis of the changes observed in two-dimensional electrophoresis identified a number of proteins previously implicated in the disease pathology, including complement factor H (CFH) precursor and alpha-2-macroglobulin (alpha-2M). Using semi-quantitative immunoblotting, the elevation of CFH and alpha-2M was shown to be specific for Alzheimer's disease and to correlate with disease severity although alternative assays would be necessary to improve sensitivity and specificity. These findings suggest that blood may be a rich source for biomarkers of Alzheimer's disease and that CFH, together with other proteins such as alpha-2M may be a specific markers of this illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Global Deterioration Scale for assessment of primary degenerative dementia
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,986
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961 · cited 8×
“There is a wide variation in normal plasma levels of CFH (Esparza-Gordillo et al., 2004) and recently polymorphic variation in the gene encoding CFH has been strongly associated with age-related macular degeneration (AMD) (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005).”
InfluentialCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Mullins, R. F., Russell, S. R., Anderson, D. H., & Hageman, G. S. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.7.835 · Cited by 937
The human complement factor H: functional roles, genetic variations and disease associations
RODRIGUEZDECORDOBA, S., ESPARZAGORDILLO, J., GOICOECHEADEJORGE, E., LOPEZTRASCASA, M., & SANCHEZCORRAL, P. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.02.005 · Cited by 574
Microvascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices
Bauer, J., Strauss, S., Schreiter-Gasser, U., Ganter, U., Schlegel, P., Witt, I., Yolk, B., & Berger, M. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80737-n · Cited by 483
Johnson, L. V., Leitner, W. P., Rivest, A. J., Staples, M. K., Radeke, M. J., & Anderson, D. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192203399 · Cited by 447
Strauss, S., Bauer, J., Ganter, U., Jonas, U., Berger, T., & Volk, B. (1992) · PubMed · Cited by 331
Differences among techniques for high‐abundant protein depletion
Zolotarjova, N., Martosella, J., Nicol, G., Bailey, J., Boyes, B. E., & Barrett, W. C. (2005) · PROTEOMICS · doi:10.1002/pmic.200402021 · Cited by 282
Biomarkers of Alzheimer disease in plasma
Irizarry, M. C. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.226 · Cited by 268
The 2 and 4 Alleles of the Apolipoprotein Gene Are Associated with Age-Related Macular Degeneration
Baird, P. N. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-1121 · Cited by 201
Mining biomarkers in human sera using proteomic tools
Zhang, R., Barker, L., Pinchev, D., Marshall, J., Rasamoelisolo, M., Smith, C., Kupchak, P., Kireeva, I., Ingratta, L., & Jackowski, G. (2004) · PROTEOMICS · doi:10.1002/pmic.200300495 · Cited by 184
Genetic and environmental factors influencing the human factor�H plasma levels
Esparza-Gordillo, J., Soria, J. M., Buil, A., Almasy, L., Blangero, J., Fontcuberta, J., & Rodr�guez de C�rdoba, S. (2004) · Immunogenetics · doi:10.1007/s00251-004-0660-7 · Cited by 167
Is Age-related Maculopathy Associated with Alzheimer's Disease?: The Rotterdam Study
Klaver, C. C. W., Ott, A., Hofman, A., Assink, J. J. M., Breteler, M. M. B., & de Jong, P. T. V. M. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010105 · Cited by 162
Hampel, H. J., Mitchell, A. J., Blennow, K., Frank, R., Brettschneider, S., Weller, L. J. R., & M�ller, H.-J. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-003-0065-z · Cited by 147
Lopez, M. F., Mikulskis, A., Kuzdzal, S. A., Bennett, D. A., Kelly, J., Golenko, E. E., DiCesare, J. L., Denoyer, E. R., Patton, W. F., Ediger, R., et al. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.053090 · Cited by 137
Detection of complement alternative pathway mRNA and proteins in the Alzheimer’s disease brain
Strohmeyer, R., Shen, Y., & Rogers, J. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00149-2 · Cited by 123
Effect of Immunoaffinity Depletion of Human Serum during Proteomic Investigations
Yocum, A. K., Yu, K. H., Oe, T., & Blair, I. A. (2005) · Journal of Proteome Research · doi:10.1021/pr0501721 · Cited by 120
Nath, A., Hall, E., Tuzova, M., Dobbs, M., Jones, M., Anderson, C., Woodward, J. G., Guo, Z., Fu, W., Kryscio, R. J., et al. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:1:29 · Cited by 119
Add Alzheimer's disease to the list of autoimmune diseases
D’Andrea, M. R. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2004.08.024 · Cited by 113
DeKosky, S. T., Ikonomović, M. D., Wang, X., Farlow, M. R., Wisniewski, S. R., López, O. L., Becker, J. T., Saxton, J. A., Klunk, W. E., Sweet, R. A., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10414 · Cited by 98
Complement Protein Isoforms in CSF as Possible Biomarkers for Neurodegenerative Disease
Finehout, E. J., Franck, Z., & Lee, K. H. (2005) · Disease Markers · doi:10.1155/2005/806573 · Cited by 95
Strohmeyer, R., Ramirez, M., Cole, G. J., Mueller, K., & Rogers, J. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00272-2 · Cited by 89
Bio-support vector machines for computational proteomics
Yang, Z. R., & Chou, K. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg477 · Cited by 87
Ceruoplasmin Is Increased in Cerebrospinal Fluid in Alzheimerʼs Disease but Not Parkinsonʼs Disease
Loeffler, D. A., DeMaggio, A. J., Juneau, P. L., Brickman, C. M., Mashour, G. A., Finkelman, J., Pomara, N., & LeWitt, P. A. (1994) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199408030-00005 · Cited by 78
Proteomic Identification of Lower Apolipoprotein A-I in Alzheimer’s Disease
Liu, H., Hu, C., Chang, J., Sung, S., Lee, L.-S., Yuan, R.-Y., & Leu, S. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000090676 · Cited by 76
Biroccio, A., Boccio, P. D., Panella, M., Bernardini, S., Ilio, C. D., Gambi, D., Stanzione, P., Sacchetta, P., Bernardi, G., Martorana, A., et al. (2006) · PROTEOMICS · doi:10.1002/pmic.200500285 · Cited by 75
Blood-Brain Barrier Damage Induces Release of α2-Macroglobulin
Cucullo, L., Marchi, N., Marroni, M., Fazio, V. J., Namura, S., & Janigro, D. (2003) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m200077-mcp200 · Cited by 60
Hampel, H. J., Kötter, H. U., Padberg, F., rschenhausen, D. A. K., & ller, H.-J. R. M. (1999) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199903000-00002 · Cited by 59
Hampel, H. J., Müller-Spahn, F., Berger, C., Haberl, A., Ackenheil, M., & Hock, C. (1995) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106969 · Cited by 48
The Use of Biomarkers in the Elderly: Current and Future Challenges
Sunderland, T., Gur, R. E., & Arnold, S. E. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.016 · Cited by 41
Depletion and fractionation technologies in plasma proteomic analysis
Tam, S. W., Pirro, J. P., & Hinerfeld, D. A. (2004) · Expert Review of Proteomics · doi:10.1586/14789450.1.4.411 · Cited by 39
Macular degeneration and elevated serum ceruloplasmin.
Newsome, D. A., Swartz, M., Leone, N. C., Hewitt, A. T., Wolford, F., & Miller, E. D. (1986) · PubMed · Cited by 19
α2-Macroglobulin Deletion Polymorphism and Plasma Levels in Late Onset Alzheimer's Disease
Scacchi, R., Ruggeri, M., Gambina, G., Martini, M. C., & Corbo, R. M. (2002) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2002.052 · Cited by 16
A Role For Protease Inhibitors in Immunity of Long-Lived Animals
Armstrong, P. B., & Quigley, J. P. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-1291-2_13 · Cited by 12
Immunoglobulin G subclasses in older persons with Down syndrome
Mehta, P. D., Dalton, A. J., Mehta, S. P., Percy, M. E., Sersen, E. A., & Wisniewski, H. M. (1993) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(93)90172-u · Cited by 9
Cited by
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702
At the interface of sensory and motor dysfunctions and Alzheimer’s disease.
Albers, M. W., Gilmore, G. C., Kaye, J., Murphy, C., Wingfield, A., Bennett, D. A., Boxer, A. L., Buchman, A. S., Cruickshanks, K. J., Devanand, D. P., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.514 · Cited by 589
Metadata
- Authors
- Hye, A., Lynham, S., Thambisetty, M., Causevic, M., Campbell, J., Byers, H. L., Hooper, C., Rijsdijk, F., Tabrizi, S. J., Banner, S., Shaw, C. E., Foy, C., Poppe, M., Archer, N., Hamilton, G., Powell, J., Brown, R. G., Sham, P., Ward, M., & Lovestone, S.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-11-01
- Volume
- 129
- Issue
- 11
- Pages
- 3042-3050
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2047219385
- Cited by
- 464
- References
- 39
- FWCI
- 15.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.